3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
33
Carcinoma, Non-Small-Cell Lung
23
Lung Neoplasms
11
Triple Negative Breast Neoplasms
3
Recurrence
3
Esophageal Squamous Cell Carcinoma
3
Neoplasms
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Hodgkin Disease
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Thoracic Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Prostatic Neoplasms
1
Primary Breast Cancer
1
Pathologic Residual Cancer Cells
1
Ovarian Neoplasms
1
Osteosarcoma
1
Nonhematologic Malignancies
1
Non-small Cell Lung Cancer Stage â…¡
1
Non-small Cell Lung Cancer Metastatic
1
Neuroblastoma
1
Neoplasms, Connective and Soft Tissue
1
Neoplasm Metastasis
1
NSCLC
1
Interventions
camrelizumab
2
apatinib
2
sintilimab
1
Vinorelbine
1
Pemetrexed
1
Gemcitabine
1
Erlotinib Hydrochloride
1
Docetaxel
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Respiratory Tract Diseases
×
Vinorelbine
×
Clear all
NCT03402048
2020-11-04
EPIC
University of Turin, Italy
Phase 3
Unknown
567 enrolled